LEXINGTON, MA, USA I July 16, 2025 I Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic ...

We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis ...

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in adults with transfusion-dependent anemia with very low, low, and ...

SEONGNAM, South Korea I July 17, 2025 I SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to ...

PITTSBURGH, PA, USA I July 18, 2025 I Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, ...

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial ...

First-in-human study of MOMA-341 focuses on advanced or metastatic solid tumors with high microsatellite instability - ...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, ...

LONDON, UK and NEW YORK, NY, USA I July 16, 2025 I OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing ...

NEW YORK, NY, USA I July 15, 2025 I SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical ...

SYDNEY, Australia I July 14, 2025 I Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to ...